FDA Grants AbGenomics AbGn-168H (Neihulizumab) Orphan Drug Designation
Rong-Hwa Lin, PhD. Chief Executive Officer of AbGenomics, was invited to be the main speaker of World ADC, will present the progress of AbGn-107 for the treatment of GI tumors at the Word ADC San Diago 2017 in September.
AbGenomics was invited to the "World ADC Summit Berlin 2017" presented the progress of AbGenomics’ ADCs, an antibody drug conjugate to treat cancer.
AbGenomics obtains FDA approval to conduct the Phase 1 clinical trial for AbGn-107 as a treatment for pancreatic, gastric and colorectal cancers.
AbGenomics demonstrated the proof of initial efficacy in a Phase-2a clinical trial study of AbGn-168H in patients with psoriatic arthritis.
The Phase 1b clinical trial for AbGn-168H in aGvHD received approval from the FDA and was led by Stanford Health Care.
AbGn-168H’s phase-II clinical trial targeting psoriasis completed in the United States.
Phase-2a clinical trial for the use of AbGn-168H in treating psoriatic arthritis approved by the FDA and initiated.
Phase 2 clinical trial for AbGn-168H targeting psoriasis with increasing dose, initiate in the U.S.
Phase 2a clinical trial for AbGn-168H completed in the U.S.
AbGenomics developed AbGn-107, an antibody drug conjugate to treat cancer, and applied for a patent from the USPTO. AbGn-107 enriched the AbGenomics’ pipeline and was a new drug for the global market.
A Phase 2a clinical trial for AbGn-168H (targeting psoriasis) received approval from the FDA to initiate trial in the U.S.
Boehringer Ingelheim completed the Phase 1 clinical trial study of AbGn-168H. A single dose intravenous injection was given to healthy male volunteers in Germany.
Boehringer Ingelheim was approved by the EU to conduct Phase 1 clinical trial of AbGn-168 to treat psoriasis. The trial used intravenous injection to deliver a single dose in healthy male volunteers.
Boehringer Ingelheim was approved by the FDA to conduct further Phase 1 clinical trials of AbGn-168 to treat psoriasis. This trial tested an intravenous injection with a single dose and was conducted in the United States and Germany.
Boehringer Ingelheim was approved by the FDA to conduct a Phase 1 clinical trial of AbGn-168 to treat psoriasis.
AbGenomics Cooperatief U.A. founded AbGenomics B.V. (AbGBV) in the Netherlands and founded AbGenomics B.V. Taiwan Branch (AbGBVTW) to continue investments in R&D resources in Taiwan.
AbGCV founded AbGenomics Cooperatief U.A. (AbGCOOP) in the Netherlands to comply with the new drug licensing agreements in the European Union.
BioAlliance C.V. (AbGCV) established in the Netherlands by AbGUS in order to obtain international patents.
AbGenomics International Inc. (AbGUS) formed in the United States to exchange information and handle licensing negotiations as well as strategic cooperation between North American pharmaceutical and biotech companies.
Boehringer Ingelheim and AbGenomics corporation signed a license agreement for the “Therapeutic Monoclonal Antibody-168”.
AbGenomics developed a monoclonal antibody treatment for colorectal cancer--AbGn-7. Proof of efficacy established through animal testing. AbGenomics filed a patent application with the USPTO.
AbGenomics developed AbGn-168, a monoclonal antibody treatment for multiple immune diseases and filed a patent application with the USPTO.
AbGenomics developed AbProtTM, AbScreenTM for DNA vaccines. The RNA molecules induce antibody immune responses.